• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care


Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.

Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI at OM1, talked with MHE editors about the importance of patient acceptance in the adoption of AI in healthcare, emphasizing the need for trust and transparency in AI tools.

Zabinksi highlighted the growing familiarity of patients with AI through general use in daily life but cautioned the importance of building trust in healthcare. He stressed that AI should complement and support clinicians rather than replace them.

In addition, he shared supporting evidence of increasing comfort with AI among patients but noted the ongoing need for trust-building efforts.

"It's a very powerful set of tools that give significant advantages in some areas over tools that exist, but it's not perfect. It's not magic, it's not always right," he said.

Regarding dermatology's acceptance of AI, Zabinski noted the field's interest in innovative data-driven tools while maintaining a practical outlook on their usefulness in practice.

He suggested that dermatology, like other medical specialties, is not yet saturated with AI tools but is on the path towards adoption.

Though, there is potential of AI in dermatology, particularly in image analysis for diagnosing rare diseases and closing gaps in diagnosis and treatment, he said.

When discussing the visual component of dermatology, Zabinski acknowledged the advantages of AI in analyzing visual information to aid in triage and diagnosis.

However, he cautioned against bias and misrepresentation in AI training and application, especially concerning skin types and appearances.

Zabinski stressed the importance of representative training data and careful use of AI tools to avoid causing harm and undermining trust in dermatology.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.